featured
Benefits of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma With Papillary Features
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
J. Clin. Oncol 2016 Sep 06;[EPub Ahead of Print], MH Voss, AM Molina, YB Chen, KM Woo, JL Chaim, DT Coskey, A Redzematovic, P Wang, W Lee, SD Selcuklu, CH Lee, MF Berger, SK Tickoo, VE Reuter, S Patil, JJ Hsieh, RJ Motzer, DR FeldmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.